University of Florida
VC Fund
Gainesville, United States
University of Florida is an educational and research institution. It provides associate, bachelors, masters, doctoral, and professional degrees in the languages, arts, sciences, engineering, media, distance education, and part time programs. University of Florida was founded in 1853 and is based in Gainesville, Florida. The university has endowmentassets worth $730.6 million.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries University of Florida invests in
Stages University of Florida invests in
Countries University of Florida invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Baba Vemuri
|
|||
|
Beverly Jones
|
|||
Daniel Ferris
|
|||
Derek Archer
|
|||
|
G. Martin Wynkoop
|
|||
| See all 9 contacts → | |||
Investment Focus
Industry
- Health Care 1 (50%)
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Baba Vemuri
Professor
|
Professor | Total investments: 0 | Find email | |
|
Beverly Jones
Adjunct Assistant Professor in the Department of Pathology, Immunology & Laboratory Medicine
|
Adjunct Assistant Professor in the Department of Pathology, Immunology & Laboratory Medicine | Total investments: 0 | Find email | |
|
Daniel Ferris
Professor of Engineering Innovation
|
Professor of Engineering Innovation | Total investments: 0 | Find email | |
|
Derek Archer
Graduate Research Assistant
|
Graduate Research Assistant | Total investments: 0 | Find email | |
|
G. Martin Wynkoop
Entrepreneur-in-Residence
|
Entrepreneur-in-Residence | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Atsena Therapeutics
|
Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases. Their clinical programs include therapies for X-linked retinoschisis (XLRS) and GUCY2D-associated Leber congenital amaurosis (LCA1). Atsena utilizes an adeno-associated virus (AAV) technology platform, including a novelspreading capsid (AAV.SPR), to target specific retinal conditions. Their ongoing research aims to prevent blindness caused by genetic mutations and is powered by their innovative approach to ocular gene therapy. | $55M / Series A / Dec 16, 2020 | |
|
Atsena Therapeutics
|
Atsena Therapeutics is a clinical-stage gene therapy company focused on developing treatments for inherited retinal diseases. Their clinical programs include therapies for X-linked retinoschisis (XLRS) and GUCY2D-associated Leber congenital amaurosis (LCA1). Atsena utilizes an adeno-associated virus (AAV) technology platform, including a novelspreading capsid (AAV.SPR), to target specific retinal conditions. Their ongoing research aims to prevent blindness caused by genetic mutations and is powered by their innovative approach to ocular gene therapy. | $8.2M / Series A / Apr 01, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does University of Florida invest in?
University of Florida invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact University of Florida?
Public channels for University of Florida include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at University of Florida?
The team at University of Florida includes Baba Vemuri (Professor), Beverly Jones (Adjunct Assistant Professor in the Department of Pathology, Immunology & Laboratory Medicine) and Daniel Ferris (Professor of Engineering Innovation), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
